Stephens Reiterates “Equal Weight” Rating for OncoCyte (NASDAQ:OCX)

OncoCyte (NASDAQ:OCX)‘s stock had its “equal weight” rating restated by Stephens in a research note issued on Wednesday, Benzinga reports. They currently have a $4.00 price objective on the stock. Stephens’ target price would indicate a potential upside of 56.25% from the company’s current price.

Other analysts also recently issued reports about the stock. StockNews.com began coverage on shares of OncoCyte in a research report on Friday, April 12th. They set a “sell” rating on the stock. Benchmark restated a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, OncoCyte has an average rating of “Hold” and an average target price of $3.90.

OncoCyte Trading Down 1.2 %

Shares of NASDAQ:OCX opened at $2.56 on Wednesday. The company’s 50-day moving average price is $2.94 and its 200 day moving average price is $3.05. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $6.20.

Insider Buying and Selling

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were acquired at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were acquired at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Andrew Arno bought 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now directly owns 69,054 shares in the company, valued at $203,709.30. The disclosure for this purchase can be found here. Insiders have acquired 2,457,288 shares of company stock worth $7,176,400 in the last ninety days. 1.94% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of OncoCyte during the second quarter valued at approximately $25,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of OncoCyte during the first quarter valued at approximately $25,000. Renaissance Technologies LLC raised its holdings in shares of OncoCyte by 131.7% during the second quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock valued at $32,000 after acquiring an additional 78,500 shares during the period. DCF Advisers LLC raised its holdings in shares of OncoCyte by 107.0% during the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after acquiring an additional 13,000 shares during the period. Finally, Balyasny Asset Management LLC raised its holdings in shares of OncoCyte by 389.9% during the third quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after acquiring an additional 42,091 shares during the period. 55.35% of the stock is owned by hedge funds and other institutional investors.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.